Published on October 26, 2021 – Updated on October 26, 2021

Two First into-human clinical trials are currently conducted in our team. The first is a molecular imaging trial which explores the capacity of the [99mTc]Tc-NTP15-5 to diagnose cartilage disease. The second one is an internal radiotherapy trial, a field in high expansion in NM. Its main objective will to test [l131I]ICF01012, a new radiotracer for the treatment of metastatic melanoma.

65 yr patient with metastatic melanoma. SPECT/CT (coronal view) performed 7 days after injection of 1400 MBq/m² of [131I]ICF01012. Peritoneal lesion with central necrosis (arrow). First into humal clinical trial

65 yr patient with metastatic melanoma. SPECT/CT (coronal view) performed 7 days after injection of 1400 MBq/m² of [131I]ICF01012. Peritoneal lesion with central necrosis (arrow). First into humal clinical trial

 [99mTc]Tc-NTP 15-5 tracer has an high affinity for the proteoglycans which are highly expressed in cartilage  matrix. Two different profiles of patient will be included in our study, some with only unilateral painful knee osteoarthritis and others with ER positive early breast cancer with intention to treat with inhibitors of aromatase. Patients with chondrosarcoma, a highly proteoglycan-rich tumor, will also be focused upon in a future trial.  Structural and functional modifications of cartilage tissue will be addressed by a change of the tracer accumulation in all studies.

[131I]ICF01012 radiolabeled with iodine-131 belongs to the benzamide tracers family and have a strong affinity for melanin. Phase I study (MELRIV) is presently conducted to measure the toxicity of the radiotracer on metastatic melanoma. Our innovative theranostic strategy implies to select patients with at least one pigmented metastasis through diagnostic imaging and then treat them with a therapeutic activity of [131I]ICF01012. The other originality of our protocol is to propose a personalized predictive dosimetry, extrapolated from an imaging sequence during the diagnostic phase. Depending on the absorbed dose to non-target organs with a risk of toxicity, this predictive dosimetry may or may not allow passage to the therapeutic phase. This work will be completed by preclinal studies exploring specifically α, β, μ parameters of kidney, liver and retina. These data  will be added in future clinical trials to optimize  non-target organs / tumor absorbed dose.
The research programs are funded by INCA DGOS; La Ligue contre le Cancer and CAP 20-25 i-site Clermont Project

 

Other GCCA Partners

  • Jean PERRIN Comprehensive Cancer Center- Nuclear Medicine Department
  • Jean PERRIN Comprehensive Cancer Center - CIRMEN : Center for Innovation and Research in Nuclear Medicine
  • Jean PERRIN Comprehensive Cancer Center – Clinical Research Division
  • Jean PERRIN Comprehensive Cancer Center - Medical Oncology Department
  • Clermont-Ferrand University Hospital - Dermatology Department
  • Clermont-Ferrand University Hospital - Rheumatology Department